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The aim of this study was to characterise the pharmacokinetics of the anticancer agent topotecan, and explore the influence
of patient covariates and interoccasion variability on drug disposition. Data were obtained from 190 patients who received the
drug as a 30-min infusion (N¼72) or orally (N¼118). The population model was built with the use of NONMEM to identify
candidate covariates, and obtain models for clearance (CL) and volume of distribution. The final models were based on first-order
absorption with lag-time (oral data), and a two-compartment model with linear elimination from the central compartment. The
Cockcroft–Gault creatinine clearance (CrCl) and WHO performance status (PS) were the only significant covariates:
CL¼(12.8þ2.1 CrCl) (1 0.12 PS). For the volume of distribution, a correlation was found between body weight and the
central volume (V1)¼0.58 body weight. Based on the structural models, a limited-sampling strategy was developed with minor
bias and good precision that can be applied a posteriori using timed samples obtained at 1.5, and 6h after the administration of
topotecan. In conclusion, a population pharmacokinetic model for topotecan has been developed that incorporates measures of
renal function and PS to predict CL. In combination with drug monitoring, the limited sampling strategy allows individualised
treatment for patients receiving oral topotecan.
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Topotecan (9-dimethylaminomethyl-10-hydroxycamptothecine) is
a water-soluble semisynthetic analogue of camptothecin that binds
to topoisomerase I–DNA complexes, leading to single-stranded,
protein-associated DNA breakage and cellular cytotoxicity. The
drug is poorly bound to plasma proteins, but is present under open
hydroxy acid and closed lactone forms within the plasma,
according to a relatively constant ratio determined primarily by
pH (Herben et al, 1996). Topotecan (Hycamtin
s) has demon-
strated antitumour activity in several tumour types, including
ovarian cancer and small-cell lung cancer (Brogden and Wiseman,
1998; Ormrod and Spencer, 1999). The drug presents the
requirements for considering therapeutic drug monitoring; its
interindividual pharmacokinetic variability is significant and
relationships are described between the area under the plasma
concentration–time curve (AUC) and its dose-limiting toxicity
(i.e. neutropenia) (Grochow et al, 1992; Rowinsky et al, 1994; van
Warmerdam et al, 1995).
Previous investigations have shown that, by considering patient
covariates (i.e. body weight, serum creatinine, and sex), the
accuracy of prediction of topotecan clearance (CL) can be
improved only partly (Gallo et al, 2000; Montazeri et al, 2000;
Mould et al, 2002). Moreover, clinical protocols are based on
repeated daily administrations (usually, 5 consecutive days) giving
the opportunity to perform a dose adjustment according to the
observed exposure on Day 1. The intrapatient pharmacokinetic
variability of topotecan following the intravenous (i.v.) or oral
administration is limited (Loos et al, 2000; Montazeri et al, 2000).
Pharmacokinetically guided dosing methods have been performed
both in adults and in children for topotecan given by i.v.
administration (Stewart et al, 1994; Montazeri et al, 2002).
However, the oral route of administration for topotecan is
attractive as it allows dosing for prolonged periods of time in an
outpatient setting. The oral bioavailability of topotecan is
approximately 30–40% (Schellens et al, 1996; Kruijtzer et al,
2002). These previous data were obtained using conventional
pharmacokinetic analyses performed in only limited number of
patients (not more than 12). In contrast, population pharmacoki-
netic analyses present the advantage of the ability to discriminate
between the several sources of variability.
Here, a large data set of topotecan plasma concentrations was
built from data obtained after various schedules of i.v. and oral
administration, either given as a single agent or in combination
with cisplatin. The goals of the current population pharmacoki-
netic analysis were (i) to quantify simultaneously the different
sources of variability on the pharmacokinetic parameters; (ii) to
update a previous covariate model for predicting topotecan
pharmacokinetic parameters; and (iii) to develop a limited
sampling strategy based on Bayesian analysis that can be applied
to oral administration of topotecan.
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lPATIENTS AND METHODS
Patient population
Data were obtained from 190 patients who participated in
five separate clinical trials (173 patients), or who had a
drug monitoring for other reasons (17 patients). All patients
provided written informed consent to participate in the respective
protocols, as approved by the local or regional ethical committees.
The patient characteristics are shown in Table 1, and a brief listing
of the study designs is given in Table 2. Topotecan was
administered i.v. (72 patients) over 30min daily for 5–13
consecutive days at a dose ranging from 0.2 to 2.4mgm
 2day
 1,
or was administered orally (118 patients) using drug formulated in
gelatine capsules at dose levels ranging from 0.15 to
2.7mgm
 2day
 1 for 5–21 consecutive days.
Blood sampling and plasma topotecan analysis
The total number of available plasma samples was 2064; two to
21 per patient (median, 15) in cycle 1 and two to 18 per patient
(median, 7) in cycle 2. The pharmacokinetic analysis
was performed on day 1 of cycle 1 (190 patients), after the
last administration of cycle 1 (175 patients), on day 1 of cycle 2
(93 patients), and after the last administration of cycle 2
(47 patients).
Topotecan concentrations in the plasma were determined as the
total of lactone and carboxylate forms (i.e. as total drug) using
high-performance liquid chromatography (HPLC) as previously
described (de Jonge et al, 2000; Montazeri et al, 2002). The lower
limits of quantification were 0.5 (Toulouse) and 0.1ngml
 1
(Rotterdam), and the mean percentage deviation from nominal
values (accuracy) and precision (within-run and between-run
variability) of quality control samples simultaneously run during
the analysis was always less than 15%.
Pharmacokinetic analyses
Concentration vs time profiles of total topotecan in plasma were
analysed using NONMEM (Beal and Sheiner, 1982) (version V,
level 1.1) with the first-order conditional estimation method and
the PREDPP package running on a personal computer. A
proportional error model was used for the interpatient variabil-
ities.
Relationships between covariates and pharmacokinetic
parameters
In total, 17 patients’ covariates were tested: age, albuminemia,
bilirubinaemia, body surface area (BSA), body weight, cisplatin
pretreatment (either as previous regimen or concurrent regimen
on day 1 and cisplatin), Cockcroft–Gault creatinine clearance
(CrCl), gender, haemoglobinaemia, proteinaemia, serum alanine
transaminase (ALT), serum aspartate transaminase (AST), serum
creatinine, and WHO performance status (PS). Interoccasion
variability (Karlsson and Sheiner, 1993) was used in order to take
into account random variability on pharmacokinetic parameters
between the first and the last day of topotecan administration. In
analysing the data, NONMEM computed the value of a statistical
function (i.e. the minimal value of the objective function), which is
equal to minus twice the log likelihood. For testing of the
covariates, the different models were compared using the
approximation to the w
2 distribution of the objective function
value of the reduced model minus that of the full model. The
number of degrees of freedom is equal to the difference in the
number of parameters between two nested models.
Intraindividual variability between cycles 1 and 2
All data (i.e. from day 1 of cycle 1 to the last day of topotecan
administration of cycle 2) were analysed to evaluate the intercycle
variability. The final covariate model obtained during the first step
of the analysis was used. Interoccasion variability was used in
order to take into account random variability between cycles 1 and
2.
Development of a limited sampling strategy for oral
topotecan
Seven times intervals for the blood collection were composed from
the oral data: (0.9–1.2) (referred to 1h henceforth), (1.4–1.6)
(1.5h), (1.8–2.2) (2h), (2.8–3.3) (3h), (3.9–4.1) (4h), (5.9–6.3)
(6h), and (7.8–8.2) (8h) h after oral administration. Among the
data from the 118 patients who received topotecan orally, two
groups of patients (N¼15, each) were randomly constituted: a
training group and a validation group. Bayesian estimation was
performed to determine the topotecan AUC from a limited number
of samples. The data (day 1 of cycle 1) from the training group
were used to select the best three-sample schedule among 23
different combinations of three samples. The predictive perfor-
mance of this schedule was prospectively evaluated using the data
of the validation group. For a patient j of the test group, the
Table 1 Characteristics of the 190 patients studied
Characteristics Mean (range)
Age (year) 55 (18–76)
BSA (m
2)
a 1.80 (1.36–2.44)
Body weight (kg) 70 (42–117)
Serum creatinine (mmoll
 1) 87 (41–162)
Creatinine clearance (mlmin
 1)
b 80 (33–167)
Number
WHO performance status: 0/1/2/3 79/98/11/2
Previous chemotherapy 141
Cisplatin pretreatment
During previous regimen 115
On day 1 of topotecan treatment 30
aCalculated according to the Dubois formula.
bCalculated according to the
Cockcroft–Gault equation.
Table 2 Characteristics of clinical studies used in pooled analysis
Route n Indication and study type Duration of therapy Dose (mgm
 2 per day)
i.v. 39 Ovarian cancer; individual dosing
a Once daily for 5 days every 3 week 0.2–2.4
i.v. 16 Solid tumour; phase I Once daily for 5, 7, 10, or 13 days 0.2–1.0
Oral 55 Solid tumour; phase I
b Once or twice daily for 5, 10, or 21 days 0.15–2.7
Oral 55 Solid tumour; phase I combined with cisplatin
c Once daily for 5 days every 3 week 0.75
Oral 8 Solid tumour; combined with cisplatin Once daily for 5 days every 3 week 0.45–0.6
i.v. 17 Ovarian cancer; therapeutic drug monitoring Once daily for 5 days every 3 week 0.2–1.5
n¼number of patients.
aMontazeri et al (2002).
bGerrits et al (1999).
cLoos et al (2000).
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lrelative prediction error, pej (%), for AUC was defined as follows:
pej (%)¼(AUCLSS AUC) 100/AUC, where AUCLSS is the
Bayesian estimate of AUC for patient j, AUC is the actual AUC
that was obtained using all data points. The predictive perfor-
mance of the formula was evaluated by computing the mean
relative prediction error (me%¼N
 1P
j¼1N (pej) where N is the
number of patients¼15) as a measure of bias and the root mean
squared relative prediction error (rmse%¼[N
 1P
j¼1N (pej
2)]
1/2)
as an assessment of precision.
RESULTS
The development of the structural pharmacokinetic model
indicated that a first-order absorption with lag-time (oral data),
and a two-compartment model with linear elimination from the
central compartment best fit the topotecan plasma concentrations
vs time profiles. A combination model (i.e. additive plus
proportional) was used for the residual variability with specific
values for oral and i.v. data. Figure 1 shows two representative
examples of the fit of the topotecan plasma concentrations
observed after oral administration: one with limited interday
variability, the second with large interday variability. In terms of
interindividual variability, by considering the data at cycle 1, the
AUC, normalised to dose, presented a 4.8-fold and a 7.6-fold
variability for i.v. and oral data, respectively. In terms of interday
variability (also corresponding to the intrapatient variability
within cycle 1), the percentage of change in AUC, normalised to
dose and expressed as the root mean squared relative prediction
error, was 22.5 and 43.0% for i.v. and oral data, respectively.
Relationships between covariates and pharmacokinetic
parameters
During individual testing of the 17 covariates, two covariates (i.e.
the Cockcroft–Gault CrCl, and the WHO PS) were significantly
correlated with topotecan CL. For the volumes of distribution, a
correlation was found between body weight and the central volume
(V1) (a correlation between BSA and V1 was significant, but
weaker). No liver function test (i.e. serum bilirubin, ALT, AST) was
significantly correlated with bioavailability (F). Testing of the
intermediate model led to the final model that is presented in
Table 3. The proportional part and the additive part corresponding
to the residual variability associated with the final covariate model
were 11 and 0.64mgl
 1 for i.v. data, and 17% and 0.09mgl
 1 for
oral data, respectively. Difference corresponding to the additive
part between i.v. and oral data may be, at least partly, due to the
difference of limit of HPLC quantification between Toulouse and
Rotterdam analyses. Indeed, i.v. and oral data matched with
Toulouse and Rotterdam HPLC measurements, respectively.
Intraindividual variability between cycles 1 and 2
The covariate model was used with updated values for CrCl, body
weight, and PS at cycle 2. The coefficients of variation
corresponding to the intercycle variabilities on topotecan CL,
central volume of distribution (V1), and bioavailability (F) were
18, 31, and 22%, respectively. The final covariate models obtained
from the data from both cycles (i.e. CL¼(11.4þ2.5 CrCl)
 (1 0.06 PS) and V1¼0.50 body weight) were similar to
those from the data of cycle 1.
Limited sampling strategy to estimate topotecan exposure
after oral administration
The structural model was that corresponding to the final covariate
model except that PS was not taken into account. By analysis of the
data of the training group, bias and precision corresponding to the
23 three-sample schedules ranged between  4 and þ11, and 8
and 21, respectively. The best schedule considering both criteria
was 1.5, 4, and 6h, with a bias and precision of þ0.6 and 8.6%,
respectively. The three combinations of two-sample schedules
corresponding to these three time intervals were then tested, and
the best prediction corresponded to the two-sample schedule using
the data obtained at 1.5 and 6h after oral administration. These
two schedules (i.e. 1.5–4–6 and 1.5–6) were evaluated prospec-
tively using the data of the validation group. Predictive
performances are shown in Table 4. Figure 2 compares AUC
determined by considering all data concentrations and that
obtained from either the three- or the two-sample schedule.
DISCUSSION
Oral chemotherapy represents a fundamental change in contem-
porary oncology practice, driven by patient convenience (Liu et al,
1997), pharmacoeconomic issues, and the potential for improved
patient quality of life (DeMario and Ratain, 1998). The oral route
for administration is particularly attractive in the case of
topotecan. Oral topotecan has demonstrated activity and toler-
ability similar to i.v. topotecan in chemosensitive small-cell lung
cancer (von Pawel et al, 2001) and relapsed epithelial ovarian
cancer (Gore et al, 2002), and thus seems to offer patients a
convenient alternative to i.v. therapy. Each topotecan treatment
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Figure 1 Observed topotecan concentrations (data points) and model-
predicted concentrations using the interoccasion variability option: data
from one patient with minimal ( 9%, A) or large (þ104%, B) change of
AUC after administration of the same dose at days 1 and 5 (1.5mgm
 2).
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lcycle is composed of 5 days of administration and even more
prolonged schedule has been considered (Hochster et al, 1999).
One potential problem in substituting i.v. by oral administration
is a greater degree of variability in AUC because of inter- and
intraindividual differences in drug absorption. While this is
observed for all classes of oral drugs, the issue is especially critical
for cancer chemotherapy, in which a narrow therapeutic index is
frequently observed. In the current study, we applied the
population approach for quantifying the several sources of
pharmacokinetic variability using the NONMEM on a large data
set. Then the mean observed bioavailability of oral topotecan was
found to be 32.4%, which retrospectively explained the better
haematological tolerance of 2.3mgm
 2day
 1 given orally than
that of 1.5mgm
 2day
 1 i.v. (von Pawel et al, 2001; Gore et al,
2002). The interindividual variability in the bioavailability was
estimated to be 22%, whereas the intrapatient variability of F was
also limited (28% for the interday, and 22% for the intercycle
variability). Regardless, these variations represent a further factor
of variability in topotecan AUC when compared with the i.v. route
of administration. The limited bioavailability is likely due to the
affinity of topotecan for drug transporter (such as breast cancer
resistance protein) at the small intestine level (Kruijtzer et al,
2002), and not to significant first-pass hepatic metabolism.
Furthermore, we did not observe any correlation between F and
liver function tests (serum bilirubin, ALT, AST).
Several studies have shown the correlation between topotecan
plasma exposure and the percentage of decrease in white blood
cells, and that severe haematological toxicity is often associated
with the recommended dose of topotecan. Hence, determination of
factors that can explain interindividual pharmacokinetic varia-
bility may be useful for individualised dosing strategies for this
drug. The covariate analysis performed here represents a
refinement of our previous study (Montazeri et al, 2000). The
final model (Table 3) is consistent with those proposed by Gallo
et al (2000), and Mould et al (2002), who also analysed data
collected in different phase I trials. The data may be considered as
physiological, with 12.8lh
 1 corresponding to the non-renal CL,
and the coefficient 2.1 for CrCl illustrates that renal elimination of
topotecan exceeds the glomerular filtration rate due to tubular
secretion of the drug (Zamboni et al, 1998). We also observed a
limited but significant relationship between topotecan and WHO
PS; a patient with a PS of 2 has a CL, which is decreased on average
Table 3 Mean, interindividual and interday variability, and covariate models of the topotecan pharmacokinetics parameters at cycle 1
Mean (795% CI
b) DOBJ
d P %CV
c
Final covariate model
a
CL(lh
 1)¼(y1+y2 CrCl) (1 y3 PS) y1¼12.8 (4.8); y2¼2.1 (1.0); y3¼0.12 (0.09) 29
Interday variability of CL 18
Central volume: V1 (l)¼y4 body weight y4¼0.58 (0.13) 39
Interday variability of V1 49
Peripheral volume: V2 (l)¼y5 y5¼45.5 (7.0) 46
Intercompartmental clearance: Q(lh
 1)¼y6 y6¼49.2 (16.9) 80
Bioavailability: F(%)¼y7 y7¼32.4 (3.9) 22
Interday variability of F 28
Constant rate of absorption: Ka(h
 1)¼y9 y9¼1.7 (0.6) 64
Lag time (h)¼y10 y10¼0.17 (0.03) 13
%CV
b
Alternative covariate models
CL¼y1 y1¼20.1 (2.3) +62 o0.001 39
CL¼y1+y2 CrCl y1¼11.8 (4.5); y2¼1.90 (1.16) +20 o0.001 20
CL¼y1 (1 y3 PS) y1¼21.8 (3.1); y2¼0.11 (0.10) +47 o0.001 37
V1¼y4 y4¼35.2 (10.1) +27 o0.001 33
aCrCl for Cockcroft–Gault creatinine clearance (Lh
 1), PS for WHO performance status.
bConfidence interval.
cCoefficient of variation for interindividual variability (not
explained by the covariate, if any) or interday variability.
dChange in objective function by comparison with the final covariate model.
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Figure 2 Ratio plot for prospective evaluation of the limited sampling
applied to the oral administration of topotecan. Plasma AUC were
estimated on concentrations at times 1.5 and 6h (two-sample schedule),
1.5, 4, and 6h (three-sample schedule) after oral administration using
NONMEM.
Table 4 Predictive performance of Bayesian estimation of AUC of
topotecan given orally with limited sampling schedules tested in 15 patients
(me mean relative prediction error, rmse root mean squared relative
prediction error)
Sampling time
intervals (hours
postadministration)
Bias,
me (%)
Precision,
rmse (%)
Range of
prediction
error
1.5, 4, and 6h +2.3 9.3  17.0–+45.2
1.5, and 6h +2.2 10.0  17.0–+45.3
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lby 24% compared to a patient with a PS of 0. Mould et al (2002)
observed a similar impact with ECOG PS. With respect to these
consistent results, topotecan dosing should be individualised
according to these two covariates (i.e. CrCl and PS) rather than the
currently used approach based on BSA alone. The covariate PS was
previously tested during the two other previous studies, but was
not found to be as significant; it is likely due to their smaller
numbers of patients (i.e. 82, Gallo et al, 2000 and 31, Montazeri
et al, 2000). Lastly, it is interesting to note that topotecan CL was
not modified by cisplatin treatment at day 1 of topotecan cycle,
confirming the previous analysis performed at the Rotterdam
Cancer Institute (de Jonge et al, 2000).
A method to control the plasma exposure of drugs given by
multiple consecutive days is to perform a drug monitoring and
then to adjust the dose according to the target AUC values. For oral
topotecan, this method would allow to annul the impact of
interindividual variability on CL and bioavailability. The limited
number of blood samples would allow generalisation of this drug
monitoring. The three-sample schedule and Bayesian method of
analysis gave precise and unbiased estimates of the topotecan AUC
after oral administration. The two-sample schedule may also be
used with comparable performance. Only one discordant value was
obtained by both schedules. However, the intrapatient variability
(present mainly for bioavailability as shown by interday variability
of 28% for F) will limit the possibility to extrapolate overall AUC
from a unique day of drug monitoring. Again, the limited number
of samples per day may help to reiterate this exploration.
In conclusion, this analysis has quantified the several sources of
variability in topotecan AUC, depending on the route of
administration and patient covariates. A limited sampling strategy
would allow performing drug monitoring and individual dose
adjustment for oral topotecan.
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